Sutton Wealth Advisors Inc. Regenxbio Inc. Transaction History

Sutton Wealth Advisors Inc.

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Nov 07, 2023	SELL	$18.08 - $24.55 $8,714 - $11,833	-482 Closed	0 $0
Q4 2022 Nov 07, 2023	BUY	$20.4 - $24.73 $2,590 - $3,140	127 Added 35.77%	482 $10.9 Million
Q2 2022 Nov 07, 2023	SELL	$19.35 - $35.04 $3,386 - $6,132	-175 Reduced 33.02%	355 $8.77 Million
Q1 2022 Nov 07, 2023	BUY	$24.62 - $34.31 $2,314 - $3,225	94 Added 21.56%	530 $17.6 Million
Q4 2021 Nov 07, 2023	BUY	$30.19 - $40.28 $150 - $201	5 Added 1.16%	436 $14.3 Million
Q3 2021 Nov 07, 2023	SELL	$29.09 - $45.68 $6,196 - $9,729	-213 Reduced 33.07%	431 $18.1 Million
Q2 2021 Nov 07, 2023	BUY	$32.46 - $40.48 $20,904 - $26,069	644 New	644 $25 Million
Q3 2020 Nov 07, 2023	SELL	$27.01 - $40.26 $9,399 - $14,010	-348 Closed	0 $0
Q2 2020 Nov 07, 2023	BUY	$27.75 - $43.44 $5,772 - $9,035	208 Added 148.57%	348 $12.8 Million
Q1 2020 Nov 07, 2023	SELL	$21.5 - $54.2 $6,127 - $15,447	-285 Reduced 67.06%	140 $4.53 Million
Q4 2019 Nov 07, 2023	BUY	$34.54 - $44.87 $4,973 - $6,461	144 Added 51.25%	425 $17.4 Million
Q3 2019 Nov 07, 2023	BUY	$31.84 - $50.88 $8,947 - $14,297	281 New	281 $10 Million
Q2 2019 Nov 06, 2023	SELL	$42.0 - $59.29 $14,448 - $20,395	-344 Closed	0 $0
Q1 2019 Nov 06, 2023	SELL	$40.82 - $62.45 $1,061 - $1,623	-26 Reduced 7.03%	344 $19.7 Million
Q4 2018 Nov 06, 2023	SELL	$39.11 - $75.15 $1,525 - $2,930	-39 Reduced 9.54%	370 $15.5 Million
Q3 2018 Nov 06, 2023	BUY	$65.0 - $82.15 $1,885 - $2,382	29 Added 7.63%	409 $30.9 Million
Q2 2018 Nov 06, 2023	BUY	$27.2 - $74.35 $10,336 - $28,252	380 New	380 $27.3 Million

193

43.5M

58.9K

58.4K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $420M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Sutton Wealth Advisors Inc., based on Form 13F filings with the SEC.

Stay updated on Sutton Wealth Advisors Inc. with notifications on news.